Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene

BACKGROUND: Treatment options in metastatic breast cancer are limited. New therapies preferable with predictive biomarkers are needed. The aim of these trials was to investigate if gene copy number of the topoisomerase 1 gene was predictive of response to the topoisomerase inhibitor irinotecan. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Kümler, Iben, Balslev, Eva, Stenvang, Jan, Brünner, Nils, Ejlertsen, Bent, Jakobsen, Erik Hugger, Nielsen, Dorte Lisbet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567440/
https://www.ncbi.nlm.nih.gov/pubmed/31196001
http://dx.doi.org/10.1186/s12885-019-5788-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567440/
https://www.ncbi.nlm.nih.gov/pubmed/31196001
http://dx.doi.org/10.1186/s12885-019-5788-9

Ejemplares similares